The company has completed a Phase III trial of its flagship drug candidate in combination with another drug for prevention of a rare, teenage-onset disease called familial adenomatous polyposis (FAP), which often leads to colon cancer.
In 2020, CPP submitted a new-drug application for the drug’s use to prevent FAP to the U.S. Food and Drug Administration, along with a similar filing to the European Union’s drug authority.
The company plans another FAP trial to begin by the end of the year, and a Phase III trial in colon cancer survivors is underway, sponsored by the Southwest Oncology Group. Clinical trials in neuroblastoma, gastric cancer, and early-onset type-1 diabetes are underway in collaboration with various nonprofit groups, the company says.